Back to Newsroom

CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

BERKELEY HEIGHTS, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announced the presentation of preclinical data demonstrating that CYC065, a highly-selective, second-generation cyclin dependent kinase (CDK) 2/9 inhibitor prolongs survival in MYCN-addicted neuroblastoma models. The in vitro and in vivo preclinical data will be presented at the 4th Neuroblastoma Symposium, November 26-27, 2015 in Newcastle Upon Tyne, United Kingdom.

Click here to read more